Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis

Cancer Research

Volumn 65, Issue 14, 2005, Pages 6034-6041

  Jansen, Aaron P ^a   Camalier, Corinne E ^a   Colburn, Nancy H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 4; DIMETHYLBENZ[A]ANTHRACENE; INITIATION FACTOR 4A; MESSENGER RNA; ORNITHINE DECARBOXYLASE; PHORBOL 13 ACETATE 12 MYRISTATE; PROGRAMMED CELL DEATH 4; REPRESSOR PROTEIN; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN CARCINOGENESIS; SKIN CARCINOMA; TRANSLATION INITIATION;

5' UNTRANSLATED REGIONS; ANIMALS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, SQUAMOUS CELL; CYTOPLASM; DISEASE PROGRESSION; EPIDERMIS; FEMALE; LUCIFERASES; MICE; MICE, TRANSGENIC; PAPILLOMA; PROMOTER REGIONS (GENETICS); PROTEIN BIOSYNTHESIS; RNA, MESSENGER; RNA-BINDING PROTEINS; SKIN NEOPLASMS; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTOR AP-1;

EID: 22244491639     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2119     Document Type: Article

References (48)

1. Hershey JWB, Miyamoto S. Translational control and cancer. In: Sonenberg N, Hershey JWB, Matthews MB, editors. Translational control of gene: expression. New York; Cold Spring Harbor Laboratory Press; 2000. p. 637-54.
2. Holland EC, Sonenberg N, Pandolfi PP, Thomas G. Signaling control of mRNA translation in cancer pathogenesis. Oncogene 2004;23:3138-44.
3. Lazaris-Karatzas A, Montine KS, Sonenberg N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap. Nature 1990;345:544-7.
4. Lazaris-Karatzas A, Smith MR, Frederickson RM, et al. Ras mediates translation initiation factor 4E-induced malignant transformation. Genes Dev 1992;6:1631-42.
5. Ruggero D, Montanaro L, Ma L, et al. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 2004;10:484-6.
6. Herbert TP, Kilhams GR, Batty IH, Proud CG. Distinct signalling pathways mediate insulin and phorbol ester-stimulated eukaryotic initiation factor 4F assembly and protein synthesis in HEK 293 cells. J Biol Chem 2000;275:11249-56.
7. Eberle J, Krasagakis K, Orfanos CE. Translation initiation factor eIF-4A1 mRNA is consistently overexpressed in human melanoma cells in vitro. Int J Cancer 1997;71:396-401.
8. Eberle J, Fecker LF, Bittner JU, Orfanos CE, Geilen CC. Decreased proliferation of human melanoma cell lines caused by antisense RNA against translation factor eIF-4A1. Br J Cancer 2002;86:1957-62.
9. De Benedetti A, Harris AL. eIF4E expression in tumors: its possible role in progression of malignancies. Int J Biochem Cell Biol 1999;31:59-72.
10. Bauer C, Diesinger I, Brass N, Steinhart H, Iro H. Meese EU. Translation initiation factor eIF-4G is immunogenic, overexpressed, and amplified in patients with squamous cell lung carcinoma Cancer 2001;92:822-9.
11. Rajasekhar VK, Viale A, Socci ND, Wiedmann M. Hu X, Holland EC. Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol Cell 2003;12:889-901.
12. Ray BK, Lawson TG, Kramer JC, et al. ATP-dependent unwinding of messenger RNA structure by eukaryotic initiation factors. J Biol Chem 1985;260:7651-8.
13. Yang HS, Jansen AP, Komar AA, et al. The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol Cell Biol 2003;23:26-37.
14. Cmarik JL, Min H, Hegamyer G, et al. Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation. Proc Natl Acad Sci U S A 1999;96:14037-42.
15. Yang H-S, Jansen AP, Nair R, et al. A novel transformation suppressor, Pdcd4, inhibits AP-1 transactivation but not NF-κB or ODC transactivation. Oncogene 2001;20:669-76.
16. Yang HS, Knies JL, Stark C, Colburn NH. Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-I transactivation. Oncogene 2003;22:3712-20.
17. Colburn NH, Former BF, Nelson KA, Yuspa SH. Tumour promoter induces anchorage independence irreversibly. Nature 1979;281:589-91.
18. Colburn NH, Gindhart TD. Specific binding of transforming growth factor correlates with promotion of anchorage independence in EGF receptorless mouse JB6 cells. Biochem Biophys Res Commun 1981;102:799-807.
19. Dong Z, Ma W, Huang C, Yang CS. Inhibition of tumor promoter-induced activator protein 1 activation and cell transformation by tea polyphenols, (-)-epigallocatechin gallate, and theaflavins. Cancer Res 1997;57:4414-9.
20. Li JJ, Rhim JS, Schlegel R, Vousden KH, Colburn NH. Expression of dominant negative Jun inhibits elevated AP-1 and NF-κB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes. Oncogene 1998;16:2711-21.
21. Young MR, Li JJ, Rincon M, et al. Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. Proc Natl Acad Sci U S A 1999;96:9827-32.
22. Boutwell RX. The function and mechanism of promoters of carcinogenesis. CRC Crit Rev Toxicol 1974;2:419-43.
23. Verma AK, Conrad EA, Boutwell RK. Induction of mouse epidermal ornithine decarboxylase activity and skin tumors by 7,12-dimethyiben. Carcinogenesis 1980;1:607-11.
24. Furstenberger G, Kinzel V, Schwarz M, Marks F. Partial inversion of the initiation-promotion sequence of multistage tumorigenesis in the skin of NMRI mice. Science 1985;230:76-8.
25. Slaga TJ, Budunova IY Gimenez-Conti IB, Aldaz CM. The mouse skin carcinogenesis model. J Investig Dermatol Symp Proc 1996;1:151-6.
26. Yuspa SH. Overview of carcinogenesis: past, present and future. Carcinogenesis 2000;21:341-4.
27. Jansen AP, Camalier CE, Stark C, Colburn NH. Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity. Mol Cancer Ther 2004;3:103-10.
28. Vassar R, Fuchs E. Transgenic mice provide new insights into the role of TGF-α during epidermal development and differentiation. Genes Dev 1991;5:714-27.
29. Dlugosz AA, Glick AB, Tennenbaum T, Weinberg WC, Yuspa SH. Isolation and utilization of epidermal keratinocytes for oncogene research. Methods Enzymol 1995;254:3-20.
30. Morgenstern JP, Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 1990;18:3587-96.
31. Rincon M, Flavell RA. AP-1 transcriptional activity requires both T-cell receptor-mediated and co-stimulatory signals in primary T lymphocytes. EMBO J 1994;13:4370-81.
32. Svitkin YV, Pause A, Haghighat A, et al. The requirement for eukaryotic initiation factor 4A (eIF4A) in translation is in direct proportion to the degree of mRNA 5′ secondary structure. RNA 2001;7:382-94.
33. Yang HS, Cho MH, Zakowicz H, Hegamyer G, Sonenberg N, Colburn NH. A novel function of the MA-3 domains in transformation and translation suppressor Pdcd4 is essential for its binding to eukaryotic translation initiation factor 4A. Mol Cell Biol 2004;24:3894-906.
34. Clemens MJ, Bommer UA. Translational control: the cancer connection. Int J Biochem Cell Biol 1999;31:1-23.
35. Millet I, Phillips RJ, Sherwin RS, et al. Inhibition of NF-κB activity and enhancement of apoptosis by the neuropeptide calcitonin gene-related peptide. J Biol Chem 2000;275:15114-21.
36. Goke R, Barth P, Schmidt A, Samans B, Lankat-Buttgereit B. Programmed cell death protein 4 suppresses CDK1/cdc2 via induction of p21(Waf1/Cip1). Am J Physiol Cell Physiol 2004;287:C1541-6.
37. Rodriguez-Puebla ML, Miliani de Marval PL, LaCava M, Moons DS, Kiyokawa H, Conti CJ. Cdk4 deficiency inhibits skin tumor development but does not affect normal keratinocyte proliferation. Am J Pathol 2002;161:405-11.
38. Thompson EJ, MacGowan J, Young MR, Colburn N, Bowden GT. A dominant negative c-jun specifically blocks okadaic acid-induced skin tumor promotion. Cancer Res 2002;62:3044-7.
39. Cooper S, Young MR, Colburn N, Bowden GT. Expression of dominant negative c-jun inhibits UVB-induced squamous cell carcinoma number and size in an SKH-1 hairless mouse model. Mole Cancer Res. In press 2005.
40. Young MR, Farrell L, Lambert PF, Awasthi P, Colburn NH. Protection against human papillomavirus type 16-E7 oncogene-induced tumorigenesis by in vivo expression of dominant-negative c-jun. Mol Carcinog 2002;34:72-7.
41. Chen Y, Knosel T, Kristiansen G, et al. Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis. J Pathol 2003;200:640-6.
42. Muller-Rover S, Handjiski B, van der Veen C, et al. A comprehensive guide for the accurate classification of murine hair follicles in distinct hair cycle stages. J Invest Dermatol 2001;117:3-15.
43. Pena JC, Kelekar A, Fuchs EV, Thompson CB. Manipulation of outer root sheath cell survival perturbs the hair-growth cycle. EMBO J 1999;18:3596-603.
44. Shibahara K, Asano M, Ishida Y, Aoki T, Koike T, Honjo T. Isolation of a novel mouse gene MA-3 that is induced upon programmed cell death. Gene 1995;166:297-301.
45. Kang MJ, Ahn HS, Lee JY, Matsuhashi S, Park WY. Up-regulation of PDCD4 in senescent human diploid fibroblasts. Biochem Biophys Res Commun 2002;293:617-21.
46. Onishi Y, Hashimoto S, Kizaki H. Cloning of the TIS gene suppressed by topoisomerase inhibitors. Gene 1998;215:453-9.
47. Afonja O, Juste D, Das S, Matsuhashi S, Samuels HH. Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis. Oncogene 2004;23:8135-45.
48. Klatt P, Serrano M. Engineering cancer resistance in mice. Carcinogenesis 2003;24:817-26.